CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma - Wikidata - awgldk - TriplyDB

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

http://www.wikidata.org/entity/Q37666309

about

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Adoptive cell therapy for sarcoma Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Advantages and applications of CAR-expressing natural killer cells Utilizing chimeric antigen receptors to direct natural killer cell activity Improving natural killer cell cancer immunotherapy The role of SLAMF7 in multiple myeloma: impact on therapy.Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.CAR-modified T-cell therapy for cancer: an updated review.Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Going back to class I: MHC and immunotherapies for childhood cancer.Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Profile of elotuzumab and its potential in the treatment of multiple myeloma The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Present and Future of Allogeneic Natural Killer Cell Therapy Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies Chimeric Antigen Receptor T Cell Therapy in Hematology.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Role of Natural Killer Cells in HIV-Associated Malignancies.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Immunotherapeutic approaches to treat multiple myeloma Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.

P2860

Q26740359-BE4ECCCA-B048-4CA2-B835-1E54B3B01267 Q26751020-8647078F-6B6B-46D6-B586-AC6A78FBEFCC Q26774678-98CD4B9C-6E8A-442D-92E0-AB498B29E480 Q27009541-C4368660-BAB1-4E92-A1CD-685F0F61946E Q27318470-8D4D175B-9E6E-4FB8-878F-73A5ED02DC78 Q28078993-A01C6842-FA3C-4D9E-BDBA-1CC6D93891BF Q28079180-C3ADF96F-5855-4EE1-B038-BD3A01EE3F59 Q28080875-80CADF33-78CF-44B8-B7A7-44C3C84DAF50 Q28082868-163E5FA8-2A7E-4E4E-BFFF-163305C8843D Q28087719-AA259F90-2571-43C9-8EC1-874F6822497F Q30249167-1D1A9EB1-F15E-4E38-9F1D-AB05881EB013 Q33700795-F6ADFCA2-3C42-4167-8B52-9D029F711F8D Q33770125-9950F3A6-D02F-463D-914C-1FE4F0222A33 Q33913839-DDB3AA34-BF87-45BB-8215-79437C17DB30 Q34044213-0766ADDA-AA8F-414D-9281-3C385203AF7C Q34180695-9AB955B4-8E61-4047-9E2E-5206D26E47C2 Q35117552-B02572DC-5461-40B0-9B30-5337F45C282E Q35157421-0A43D00B-A60D-41CA-A41F-6D2D0C467606 Q35600095-462DDED1-BAEF-4672-91FD-F19D3DF809B9 Q35628678-AD582FCE-AAD6-4165-B518-04A5F74B4C88 Q35669068-47AB183B-4A9A-4B41-B398-CC1CEF555904 Q35677351-A445302D-B1D5-47E6-A4C9-36EABF646D7A Q35711209-1A9208DE-F1EC-4F6D-9948-4EF81ADFDAD2 Q35834087-EA9C92CB-F2D6-4C71-90BA-C9E8BB9220CE Q35886785-3A732D10-8D19-432E-AE07-44BDA755AB3B Q36070261-B4685D0A-E1FE-413F-8AEB-46A928969B3B Q36253378-B91836F3-A2F4-4429-B009-BAA42B37B5C1 Q36447553-299D1828-CD43-4A18-8EA8-5A592AECAF5B Q36547199-BA9B577F-6C2A-420B-B172-4D2025DA484F Q36722700-BB5ACA03-5B42-4545-BA47-BA70E75A2832 Q37058110-09181067-91C8-43CB-8D68-4DE1C3B07739 Q37376346-10793126-44B4-4E41-A9E9-1765CD286F57 Q37587956-5E72D218-0F96-44E2-87FB-A1395A1DF6AE Q37712593-39E33DE4-F745-4F8E-A54C-8B9FCF48270E Q37723469-0E2FF135-D7E6-459B-8A33-7F12E2C4FF38 Q38171067-0C462A2A-4EE7-49FC-BC5E-34A081FBBF55 Q38289029-9026572E-AA23-4BC3-82C3-ACA9A0B14931 Q38370539-2735D94C-CB56-40F7-A4C4-B85327098DBD Q38417073-E735A058-DD6F-426B-9C38-582B0208050A Q38559350-A0922384-E7C2-4121-B063-09125859E451

P2860

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

http://www.wikidata.org/entity/Q37666309

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CS1-specific chimeric antigen ...... against human multiple myeloma

@en

CS1-specific chimeric antigen receptor

@nl

type

label

CS1-specific chimeric antigen ...... against human multiple myeloma

@en

CS1-specific chimeric antigen receptor

@nl

prefLabel

CS1-specific chimeric antigen ...... against human multiple myeloma

@en

CS1-specific chimeric antigen receptor

@nl

P1433

Q37666309-BEA183F9-79AC-4857-B00F-91039691E032

P1476

Q37666309-0C7B5442-9DAD-4D5E-AF10-70C27F1BFADB

P2093

Q37666309-19D4E528-4A56-4AFF-A69D-3B4B1F7460F4

Q37666309-269BE9D5-0816-41FD-A22D-BB4BD8292A07

Q37666309-420F7850-88DF-4156-9487-0AF34AF9B415

Q37666309-4B382C66-7D21-4703-A2E2-A482D27A75F1

Q37666309-6FF68E34-CA12-401B-884B-CFBD9206EDDB

Q37666309-7C0B4B0D-EC70-4E73-AAD0-A48A1C702073

Q37666309-7D77A515-AD09-4B3C-8610-879A0EE8BA39

Q37666309-7F84BF3C-8D9B-4398-9214-56A5ACA14B0D

Q37666309-A7DAC253-5471-4281-8AC0-0B4A3CFCF083

Q37666309-ADAF1EAD-39C9-445D-A813-3F5DD08906A3

P2860

Q37666309-092625CA-D9EE-41C9-BF6D-2396A2447058

Q37666309-09B40563-5D40-4351-910A-9F00A18FA08A

Q37666309-11F2C4FC-5FA7-4E28-BAEF-02708E60191B

Q37666309-2A7BE611-E4D6-476F-9060-08AEFF458E3C

Q37666309-2BEA39CA-6F88-4FFD-9312-5B66117A7D40

Q37666309-2F929CA7-7739-4E1F-BEA7-AB8F33446F2F

Q37666309-320E4203-3713-466E-ABA5-A4666F59C417

Q37666309-351333F9-AD57-417B-9A2D-D10172D8616A

Q37666309-36ED2921-14AB-49C0-9F75-BB2B68D96040

Q37666309-4629B2F0-0531-4E88-AB83-CA558AFD1122

P2888

Q37666309-DEAB0DAE-C266-4229-A488-2EE9299D45DE

P304

Q37666309-D13D5F33-2F1E-485D-8146-9ACFFCCE17CA

P31

Q37666309-FEEE63C5-976D-4BA1-8D84-E08AEFE75559

P356

Q37666309-DB855C2A-CF9C-45E5-A81C-AD816B3BE655

P433

Q37666309-197BB024-6AC6-4119-9469-9B3FA9483AAB

P478

Q37666309-66066793-40A1-487B-AC97-F92FC5CCCC36

P50

Q37666309-10F75F39-3C7A-46AE-9C53-CB7177FF7174

Q37666309-259BA546-5E4D-4974-8543-8FD109E648DE

P577

Q37666309-2EE42B28-75D6-49FD-BA68-9F0B03C52B62

P5875

Q37666309-A6686A5D-6430-4A69-96EB-B30B5E54F2AC

P6179

Q37666309-51E57D22-88C7-4CBB-B079-FA656C0CB486

P698

Q37666309-AD83AC95-02F6-451C-BD60-9873BA5EF23D

P932

Q37666309-AF7BFA2D-E50B-4BA2-9703-6D6E62E3C604

P356

P1433

P1476

CS1-specific chimeric antigen ...... against human multiple myeloma

@en

P2093

C C Hofmeister

http://www.w3.org/2001/XMLSchema#string

D M Benson

http://www.w3.org/2001/XMLSchema#string

H Mao

http://www.w3.org/2001/XMLSchema#string

J Chu

http://www.w3.org/2001/XMLSchema#string

J Yu

http://www.w3.org/2001/XMLSchema#string

J Zhang

http://www.w3.org/2001/XMLSchema#string

K Ghoshal

http://www.w3.org/2001/XMLSchema#string

L Yi

http://www.w3.org/2001/XMLSchema#string

M A Caligiuri

http://www.w3.org/2001/XMLSchema#string

S He

http://www.w3.org/2001/XMLSchema#string

P2860

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed

A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Multiple myeloma

Cancer statistics, 2012

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology

BCMA is essential for the survival of long-lived bone marrow plasma cells

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

P2888

P304

917-927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.279

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257074064

http://www.w3.org/2001/XMLSchema#string

P6179

1050860950

http://www.w3.org/2001/XMLSchema#string

P698

24067492

http://www.w3.org/2001/XMLSchema#string

P932

3967004

http://www.w3.org/2001/XMLSchema#string